SURMOUNT-1 Trial (New England Journal of Medicine, 2022) Randomized, double-blind, placebo-controlled 2,539 participants 72 weeks NCT04184622 Tirzepatide 5 mg -16.0% Mean body weight reduction Tirzepatide 10 mg -21.4% Mean body weight reduction Tirzepatide 15 mg -22.5% Mean body weight reduction Placebo group: -2.4% All results statistically significant (p 27 with Comorbidities Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss
Phc hi da b chy nng, nng tng da trng sng t nhin rng r
Therefore, therapeutic choices should reflect both anticipated weight reduction and compound-specific benefits
I talked in last year's Obesity Society meeting
Athletes subject to testing should carefully weigh this risk, even if BPC-157 itself is not currently prohibited
Strict research-only chemical